PGT is entering a more mature phase.
For years, much of the conversation around preimplantation genetic testing focused on what we can detect.
Now the more important conversation is becoming:
What should we report?
How confident are we?
How do we explain uncertainty to patients?
And how do we make sure innovation improves care, rather than simply adding complexity?
Three trends are especially important:
1. Non-invasive PGT-A is promising, but the evidence still shows important limitations. Avoiding biopsy sounds attractive, but accuracy, false positives, and clinical validation matter.
2.Polygenic embryo testing is moving quickly, but it raises serious scientific and ethical questions. Probabilistic risk is not the same as diagnosis, and patients deserve clear counseling around what these scores can and cannot tell them.
3. AI will increasingly support embryo assessment and interpretation, but it should not become a black box. In reproductive genetics, trust depends on transparency, validation, and responsible communication.
The future of PGT should not be “more data at any cost.”
It should be better data, better interpretation, and better decisions for families and clinicians.
That is where genomics can make the biggest difference.
#PGT #PreimplantationGeneticTesting #IVF #ReproductiveGenetics #Genomics #Embryology #FertilityCare #GeneticCounseling #PrecisionMedicine #ResponsibleInnovation